Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

Key Resources and Organizations for Precision Medicine Guidelines

MedGenome Strengthens Leadership Team to Drive North American Expansion in Precision Medicine

NCCN Expands Clinical Practice Guidelines for High-Risk Genetic Cancer Assessment

MicrobioTx Launches Gut Function Test (GFT) for Easy, Affordable Gut Health Profiling

Roche to Present Over 40 Abstracts on Blood Disorders at 66th ASH Annual Meeting, Showcasing Advances in Lymphoma Treatments

Hamad Medical Corporation Hosts 3rd Precision Medicine Conference on AI and Genomics Integration

Caris Life Sciences Receives FDA Approval for Groundbreaking MI Cancer Seek™ Diagnostic Assay for Precision Oncology

IWG Proposes New Clinical-Biological Definition for Diagnosing Alzheimer’s Disease

Inify Laboratories and Karolinska Institutet's ProMort Team Partner to Transform Prostate Cancer Diagnostics with AI

Home
/
update
/
details

Pillar Biosciences and AstraZeneca Partner to Accelerate Access to Liquid Biopsy Testing

NextEdge Admin

10 Sep 2024

1 min 49 sec

Pillar Biosciences, Inc. has partnered with AstraZeneca to enhance access to molecular testing using rapid Next Generation Sequencing (NGS)-based liquid biopsy panels for detecting cancer-related genetic variants, with an initial focus on the UK and European markets. This collaboration aims to streamline the identification of tumors with actionable genomic alterations through local laboratories, accelerating diagnostic testing.

The partnership will leverage Pillar’s oncoReveal™ liquid biopsy NGS panels, including the Core LBx, Essential LBx, and Fusion LBx panels, which analyze circulating tumor DNA (cfDNA) and RNA (cfRNA). These panels can be used by any laboratory, offering results in under three days. Notably, the panels enable the testing of samples from over 22 patients in a single Illumina NextSeq™ run, enhancing scalability and cost-effectiveness.

Dan Harma, Chief Commercial Officer at Pillar, highlighted the importance of affordable, easy-to-use NGS kits for providing oncologists with actionable results in a timely manner. John Longshore, AstraZeneca's Head of Scientific Affairs, emphasized the need for decentralized NGS solutions to improve global access to targeted therapies, noting that Pillar’s panels support high-quality, rapid workflows that are integral to their mission.